Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Dihydrotanshinone I (DHTS) is a natural compound extracted from Salvia miltiorrhiza Bunge used for treating of cardiovascular diseases.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | In stock | $ 51.00 | |
10 mg | In stock | $ 92.00 | |
25 mg | In stock | $ 191.00 | |
50 mg | In stock | $ 277.00 | |
100 mg | In stock | $ 458.00 | |
500 mg | In stock | $ 987.00 |
Description | Dihydrotanshinone I (DHTS) is a natural compound extracted from Salvia miltiorrhiza Bunge used for treating of cardiovascular diseases. |
In vitro | DHT (10 nM) decreases lectin-like ox-LDL receptor-1 (LOX-1) and NADPH oxidase 4 (NOX4) expression, reactive oxygen species (ROS) production, NF-κB nuclear translocation, ox-LDL endocytosis and monocytes adhesion in lipopolysaccharide (LPS)-stimulated human umbilical vein endothelial cells (HUVECs)[1]. Dihydrotanshinone I induces caspase-dependent apoptosis induced in HCT116 cells. Dihydrotanshinone I induces concentration and ROS dependent caspase activation. Apoptosis induced by Dihydrotanshinone I is completely prevented by Z-VAD-fmk. Apoptosis induced by Dihydrotanshinone I is significantly inhibited by pretreatment of Z-LEHD-fmk but only is partially inhibited by Z-IETD-fmk. Apoptosis induced by Dihydrotanshinone I is significantly increased by caspase-2 knockdown[3]. |
In vivo | In ApoE-/- mice fed with an atherogenic diet, DHT (10 and 25 mg kg-1) significantly attenuated atherosclerotic plaque formation, altered serum lipid profile, decreased oxidative stress and shrunk necrotic core areas. DHT dramatically inhibits the enhanced expression of LOX-1, NOX4, and NF-κB in aorta[1]. Dihydrotanshinone I (1, 2, 4 mg/kg) treatment can improve cardiac function, reduce infarct size, ameliorate the variations in myocardial zymogram and histopathological disorders, decrease 20-HETE generation, and regulate apoptosis-related protein in myocardial ischemia-reperfusion rats[2]. |
Kinase Assay | Cells are treated with various concentrations of Dihydrotanshinone I (3.13-20 μM) for 48 h. For the activity assay, Ac-DEVD-AMC (1 μg/μL), Ac-IETD-AMC (1 μg/μL) or Ac-LEDH-AMC (1 μg/μL) and cell lysate are added into Protease Assay Buffer in 96-well plate. Reaction mixtures with lysis buffer are used as negative controls. Cells treated with DMSO (0.1%) are treated as vehicle control. The reaction mixtures are incubated for 1 h at 37°C. The AMC liberated from the substrates is measured using spectrofluorometer of Victor 2 plate reader with an excitation wavelength of 380 nm and an emission wavelength of 430 nm. |
Source |
Synonyms | DHTS, 15,16-dihydrotanshinone I |
Molecular Weight | 278.3 |
Formula | C18H14O3 |
CAS No. | 87205-99-0 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 3.85 mg/mL (13.82 mM), Sonification is recommended
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Dihydrotanshinone I 87205-99-0 Immunology/Inflammation Microbiology/Virology SARS-CoV ROS SARS coronavirus inhibit DHTS 15,16-dihydrotanshinone I Inhibitor inhibitor